| Name | Title | Contact Details |
|---|
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
Vitaflo USA is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hanford Pharmaceuticals is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.